HF 4065, an omnibus health care bill was signed into law by Gov. Tim Walz (D). The bill includes a provision that allows pharmacists to administer intramuscular and subcutaneous drug injections and to place drug monitoring devices according to prescription, protocols, or collaborative practice agreements.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
Before the New York State Legislature recently adjourned, both Houses passed legislation (A3040B-S4807B) which would authorize pharmacists to administer long-acting injectable medication for MH/SUD per a prescription or order. In addition, the legislature rejected efforts to delay or repeal the planned FFS (Fee for Service) transition of the pharmacy benefit set to take effect on April 1, 2023.
For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.
The Department of Medicaid (ODM (Ohio Department of Medicaid)) has published an important update regarding the implementation of the Single Pharmacy Benefit Manager (SPBM). The update clarifies that reimbursement rates for the new program will be announced later this month, that Gainwell has launched a new webpage that includes important program information and useful guides including the SPBM Pharmacy Reference Guide (Provider Manual). The website will continue to be updated with information for members, pharmacies, and prescribers. Lastly, they have also released an updated version of their SBPM FAQ (Frequently Asked Questions), which includes answers to many questions NACDS had previously submitted on behalf of members.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
The Department of Health has announced their endemic strategy for COVID-19 vaccination and testing.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
Governor Bill Lee (R) has signed HB2228, effective July 1, 2022, under this measure, prescribers are required to include a prescription for naloxone hydrochloride or another opioid overdose reversal agent with any opioid prescription. This only applies for prescriptions of more than a 3-day supply of an opioid medication, when prescribed concurrently by the same provider with a benzodiazepine, when the patient presents an increased risk for overdose, or the patient at substantial risk of witnessing an opioid overdose event. Violations of this measure are considered a Class D felony.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
On June 2, the Insurance Commission filed the Pharmacy Auditing Entities and Pharmacy Benefit Managers Rule with an effective date of July 1, 2022. This rule is pursuant to passage of HB (House Bill) 2263 of 2021. The new rule amends the current rule relating to Pharmacy Audits that was effective on April 1, 2021 and remains in effect.
Also in West Virginia, The Insurance Commission has proposed a rule 114CSR99 to reflect changes to the WV Code because of the passage of Enrolled HB 4112 which was approved by Governor Justice on March 30, 2022. The rule will be considered by the Legislative Rule Making Review Committee during the 2022 legislative interims and put before the WV Legislature for approval in 2023. If you have comments, please email them to Jill McCormack before the close of business on June 23. Otherwise, you may email them to michael.n.malone@wv.gov of the Insurance Commission by 5pm on July 5, 2022.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
Attorney General Leslie Rutledge announced a lawsuit against drug manufacturers and Pharmacy Benefit Managers (PBMs) for manipulating and inflating insulin and drug prices in Arkansas. In the complaint filed in Pulaski County, Attorney General Rutledge alleges that Novo Nordisk, Sanofi, and Eli Lilly conspired with Express Scripts, Caremark and Optum to significantly increase their revenues by unfairly and deceptively driving up the costs of insulin, making insulin, and other diabetic treatments unaffordable for many diabetics in Arkansas and creating an enormous financial burden for Arkansas consumers.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Board of Pharmacy announced its June meeting schedule.
Also in California, Gov. Gavin Newsom (D) appointed Jessica Crowley to the Board of Pharmacy. Having held a variety of positions within CVS pharmacy between 2010-2020, Dr. Crowley has been a staff pharmacist for Pavilions Pharmacy since 2020. She is a member of Lambda Kappa Sigma, United Food and Commercial Workers, the California Pharmacists Association and Phi Lambda Sigma.
Also in California, this week, the Department of Health Care Services (DHCS) announced its plans for Medi-Cal Rx Reinstatement of Claim Edits and Prior Authorizations. DHCS along with Magellan hosted a series of webinars to provide an overview of a phased approach for reinstatement of safety edits and prior authorizations and the phasing out of the Transition Policy. Stakeholder feedback has been fundamental to the reinstatement design and will remain a critical component throughout the reinstatement process. DHCS is requesting stakeholder feedback to refine the approach to reinstatement. Stakeholders who would like to submit comments may do so through the close of business on June 10 via email to Reinstatement@dhcs.ca.gov.
Finally in California, the Department of Health Care Services posted the following alerts and notices on the Medi-Cal Rx Web Portal.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
Governor JB Pritzker (D) has signed HB4595, on May 13, 2022, effective July 1, 2022, this legislation amends the state’s insurance contract and provides that a contract between a pharmacy benefit manager or third-party payer and a covered entity under the 340B program may not contain certain provisions.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.